Immuneering Corp balance sheet

At the end of fiscal 2023, Immuneering Corp had total assets of $103m, total liabilities of $12.0m and shareholders' equity of $90.6m. It held $59.4m in cash against $0 of debt: net cash of $59.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuneering Corp: balance sheet, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Cash and equivalents	37	75	73	59
Receivables	1	0	0	0
Total current assets	38	152	109	89
Goodwill	—	7	7	7
Total assets	38	167	122	103
Accounts payable	1	1	3	2
Total current liabilities	2	6	8	8
Total debt	0	0	0	0
Total liabilities	3	11	13	12
Shareholders' equity	−22	156	110	91
Non-controlling interests and other (assets − liabilities − equity)	58	—	—	—
Net debt (negative = net cash)	−37	−75	−73	−59

US$ millions unless shown otherwise. Fiscal quarters.

Immuneering Corp: balance sheet, quarterly
Quarter	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023
Receivables	0	0	0	0	0	0	0	0
Total current assets	140	129	120	109	94	112	101	89
Goodwill	7	7	7	7	7	7	7	7
Total assets	152	142	134	122	108	125	114	103
Accounts payable	2	1	2	3	3	3	2	2
Total current liabilities	4	4	7	8	6	5	6	8
Total liabilities	8	8	12	13	10	10	10	12
Shareholders' equity	144	134	122	110	98	115	104	91

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuneering Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuneering Corp.